EGFR and non-small cell lung carcinoma: To our knowledge, this is the largest meta-analysis that evaluated the optimal therapeutic choice of patients with advanced EGFR-mutated NSCLC, and also is the first one to identify the optimal therapeutic choice for elderly and non-elderly patients.